Santarus, Inc. (NASDAQ:SNTS)

CAPS Rating: 5 out of 5

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Recs

1
Player Avatar therock050383 (< 20) Submitted: 5/20/2010 12:42:24 PM : Outperform Start Price: $2.91 SNTS Score: +926.77

At this point, everyone is assuming the worst case scenario with generic Zegerid regarding Par Pharma, and this is priced into the stock....The company has over $1.50/share in cash alone....At current prices, the rest of the company flagship without the cash is priced at $72 million.....They will have $50 million in Glumetza sales this year, Merck just launched Zegerid OTC 1 1/2 months ago (in which SNTS will receive royalties moving forward), plus two late stage III drugs.....(All priced at $72 million), and they will still have $100 + million in Zegerid prescription sales this year........seems cheap.

Featured Broker Partners


Advertisement